Stay updated on Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial
Sign up to get notified when there's something new on the Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial page.

Latest updates to the Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision updated to v3.4.2; the funding-lapse notice and the prior revision notice (v3.4.1) were removed.SummaryDifference0.4%

- Check20 days agoChange DetectedA site-wide funding notice was added and the site version updated to v3.4.1, replacing the previous revision v3.4.0.SummaryDifference0.4%

- Check28 days agoChange DetectedNo core content changes; minor UI/metadata text updates were made, including Show glossary, Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedFooter revision tag updated from Revision: v3.3.3 to Revision: v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedThe Study Locations section was updated: new sites were added across several U.S. states and international locations (e.g., Alabama, Arkansas, California, Colorado, Florida, Missouri, Ohio, Tennessee, Texas, Virginia, Tel Aviv, Chiba, Tokyo, Gyeonggido, Seoul Teugbyeolsi), and several existing sites were removed.SummaryDifference2%

- Check85 days agoChange DetectedA minor revision update indicates version v3.3.2 was published; no changes to core study content, eligibility, outcomes, or locations are evident in the visible page content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial page.